Together, these studies imply that miRNAs those target ERα, contribute to the ER negativity in breast cancers and therefore, serve as potent therapeutic markers as well as targets in endocrine-resistant breast cancers (Table 1). The gene discussed is ESR1; the disease is breast carcinoma.